A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

NCT06698575 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Genital Herpes Simplex Type 2

Interventions

DRUG: ABI-1179
DRUG: ABI-1179 Placebo

Sponsor

Assembly Biosciences